Yes, patients with eosinophilic esophagitis who achieve remission on PPI therapy should continue PPI treatment long-term.
For patients with EoE who achieve histological response to PPI therapy, continuing PPI treatment is strongly recommended to maintain remission and prevent disease progression, including recurrent dysphagia, food impaction, and esophageal stricture formation. 1
Evidence Supporting Maintenance PPI Therapy
The most recent British Society of Gastroenterology (BSG) 2022 guidelines provide a strong recommendation (despite low-quality evidence) that PPI therapy appears effective in maintaining remission in patients who achieve histological response 1. This represents the highest quality guideline evidence available.
Key Supporting Data:
Sustained remission rates: Prospective data in 57 children showed 70.1% maintained long-term histological remission over 12 months on maintenance PPI therapy 1
Superior to other maintenance options: Three single-arm observational studies demonstrated that PPIs maintained sustained histological response in the majority of adults, even with dose reduction—performing better than topical steroids which showed high recurrence rates when doses were reduced 2
Prevention of complications: Maintenance therapy reduces risk of recurrent food bolus obstruction 1, and early effective treatment may prevent long-term fibrosis and stricture formation 1
Practical Implementation
Dosing Strategy:
- Induction: Omeprazole 20 mg twice daily (or equivalent) for 8-12 weeks 1
- Maintenance: Most responders maintain remission with standard PPI doses (can often step down from twice daily to once daily dosing) 3
- Step-down approach: After achieving remission on high-dose PPI, 81% of patients maintained remission when reduced to omeprazole 40 mg once daily, and 83% of those remained in remission on 20 mg once daily 3
Important Caveats:
Document the indication clearly: Ensure patients and primary care physicians understand PPIs are prescribed for EoE management, not GORD treatment, to prevent inappropriate discontinuation 1
Monitor response: Endoscopy with biopsy while on treatment is necessary to confirm histological response, as symptoms may not correlate with histological activity 1
Consider alternatives if preferred: The 2020 AGA guidelines note this is a "preference-sensitive area"—patients who place high value on avoiding long-term steroid or PPI use could reasonably choose other maintenance options (topical steroids or elimination diets), provided clinical follow-up is maintained 2
Common Pitfall to Avoid
Failure to instruct continuation: Real-world data shows that long-term PPI use often continues in EoE patients even without histological response, frequently because clinicians fail to explicitly discuss whether to continue or discontinue therapy 4. The opposite problem also occurs—inappropriate discontinuation in responders. Always explicitly address the maintenance plan after confirming response.
When to Reconsider:
If symptoms recur while on maintenance PPI therapy, repeat endoscopy with histology is recommended to assess for disease breakthrough 1. In true PPI non-responders or those with breakthrough disease, alternative therapies (topical steroids, elimination diets, or emerging biologics) should be considered 2, 1.